IRADIMED CORPORATION — Form 10-Q Summary
Reporting period: Second quarter and six months ended June 30, 2022; unaudited. IRADIMED develops, manufactures and sells MRI-compatible medical devices, accessories, disposables and services, primarily to hospitals and acute care facilities. Its principal device lines are MRI-compatible IV infusion pumps and patient vital signs monitoring systems.
Financial performance
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $12.72 million | $9.81 million | $25.03 million | $19.03 million |
| Gross profit / margin | $10.14 million / 79.7% | $7.33 million / 74.7% | $19.52 million / 78.0% | $14.39 million / 75.6% |
| Operating income | $4.17 million | $1.84 million | $7.24 million | $3.62 million |
| Net income | $3.24 million | $1.47 million | $5.73 million | $2.86 million |
| Diluted earnings per share | $0.26 | $0.12 | $0.45 | $0.23 |
- Revenue increased 29.7% in Q2 and 31.5% in the first half year over year. Device revenue rose 50.4% in Q2 and 44.5% in the first half; disposables, services and other revenue declined 1.7% in Q2 but increased 10.2% for the half.
- U.S. revenue grew 34.5% in Q2 and 35.8% in the first half; international revenue grew 7.8% and 13.9%, respectively. U.S. sales represented 85.0% of Q2 revenue, compared with 82.0% a year earlier.
- Gross margin improved, which management attributed primarily to geographic sales mix, price increases begun in the second half of 2021, and inventory cost standard updates. Higher inventory reserve adjustments and overhead variances partly offset first-half improvement.
- Q2 operating expenses were $5.97 million, up from $5.49 million. Sales and marketing and R&D costs rose, while Q2 general and administrative costs declined. For the first half, total operating expenses were $12.28 million versus $10.77 million.
Cash, liquidity and capital structure
- At June 30, 2022, cash and cash equivalents were $52.16 million; the company held no investments. Working capital was $62.4 million and stockholders’ equity was $65.9 million. At year-end 2021, cash and investments totaled $62.5 million, working capital was $69.4 million and equity was $72.2 million.
- Operating cash flow for the first half was $3.1 million, down from $4.5 million. Receivables growth and inventory purchases were cash uses; prepaid income tax changes provided a cash inflow.
- Investing activities used $0.35 million in the first half, including property and equipment purchases and capitalized intangible assets. Financing activities used $12.56 million, primarily for a $12.56 million special dividend.
- The balance sheet reports no borrowing or funded debt. It does report operating lease liabilities of approximately $2.35 million, including a related-party facility lease. Management stated current cash and expected operating cash generation should cover requirements for at least 12 months.
Outlook, risks and notable items
- Management expects higher revenue for the remainder of 2022 than in the comparable 2021 period, driven by medical devices, accessories, disposables and services. It also expects higher operating expenses, primarily sales and marketing and general and administrative costs. No numerical full-year guidance was provided.
- Key stated risks include dependence on a limited number of products, required regulatory clearances and approvals, sole-sourced components, supply-chain interruptions, competition, customer or supplier concentration, and possible continuing effects of COVID-19.
- The company noted that COVID-19 uncertainty may affect estimates, including those for intangible and other long-lived assets. It also disclosed approximately $5.83 million in purchase orders and approximately $138,000 accrued for legal matters; management said currently known legal matters are not expected to materially affect results or financial position.
- The company leases its headquarters and manufacturing facility from an entity controlled by CEO and Chairman Roger Susi. It paid that entity $237,008 in rent during the first half of 2022. The lease currently runs to May 2024, with a renewal option.
- CEO and Chairman Roger Susi received a restricted-stock-unit award valued at $750,000 in connection with the CFO appointment. John Glenn became CFO in May 2022. Management reported disclosure controls were effective and no material changes to internal control over financial reporting.
Most important facts for investors to verify
- Whether strong device-led revenue growth continues, particularly in the U.S., and whether product mix and pricing sustain gross-margin gains.
- Whether operating cash flow improves as receivables and inventory grow, and how much cash remains after the special dividend.
- Execution of management’s remainder-of-2022 outlook, including expected expense increases; the filing provides no numerical guidance.
- Exposure to regulatory decisions, sole-source components, supply continuity and the pandemic’s potential operational or asset-valuation effects.
- Terms and governance oversight of the related-party facility lease, and the status and potential exposure of accrued legal matters.